A Study of the Interaction of Omeprazole and Warfarin in Anticoagulated Patients

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1992 Dec 1

PMID 1493083

Citations 24

Authors

P Unge

L E Svedberg

A Nordgren

H Blom

T Andersson

P O Lagerstrom

J P Idstrom

Affiliations

Soon will be listed here.

Abstract

1. Thirty-five patients on continuous therapy with warfarin were given omeprazole 20 mg once daily and placebo each for 3 weeks according to a two-centre randomised double-blind cross-over design. 2. Blood samples were obtained once weekly during the run-in and follow-up periods as well as during the first 2 weeks of each treatment period, and twice during the last week of each treatment period. Plasma concentrations of R- and S-warfarin were measured by h.p.l.c. and the anticoagulant effect was assessed using the Trombotest. 3. Twenty-eight patients were evaluated. The mean plasma concentration of R-warfarin was increased by 9.5% during omeprazole treatment compared with placebo, while that of S-warfarin, the more active isomer, was unaffected. The coagulation time was not significantly changed (106 s during omeprazole and 98 s during placebo). Corresponding TT-values (Trombotest) were 8.8 and 9.9 (NS).

Citing Articles

Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants.

Zhang X, Jiao F, Li G, Yu X, Pei Y, Zhang Y Front Pharmacol. 2023; 14:1191608.

PMID: 37274098 PMC: 10235595. DOI: 10.3389/fphar.2023.1191608.

Monitoring the distribution of warfarin in blood plasma.

Rosengren A, Karlsson B, Nicholls I ACS Med Chem Lett. 2014; 3(8):650-2.

PMID: 24900525 PMC: 4025853. DOI: 10.1021/ml300112e.

Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.

Wedemeyer R, Blume H Drug Saf. 2014; 37(4):201-11.

PMID: 24550106 PMC: 3975086. DOI: 10.1007/s40264-014-0144-0.

Drug-drug interaction profiles of proton pump inhibitors.

Ogawa R, Echizen H Clin Pharmacokinet. 2010; 49(8):509-33.

PMID: 20608754 DOI: 10.2165/11531320-000000000-00000.

Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.

Vakily M, Lee R, Wu J, Gunawardhana L, Mulford D Clin Drug Investig. 2008; 29(1):35-50.

PMID: 19067473 DOI: 10.2165/0044011-200929010-00004.

References

Andersson T . Omeprazole drug interaction studies. Clin Pharmacokinet. 1991; 21(3):195-212. DOI: 10.2165/00003088-199121030-00004. View

Veronese M, Mackenzie P, Doecke C, McManus M, Miners J, Birkett D . Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 1991; 175(3):1112-8. DOI: 10.1016/0006-291x(91)91680-b. View

Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P . Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990; 47(1):79-85. DOI: 10.1038/clpt.1990.12. View

Relling M, Aoyama T, Gonzalez F, Meyer U . Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther. 1990; 252(1):442-7. View

Andersson T, Regardh C, Bertilsson L . Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit. 1990; 12(4):415-6. DOI: 10.1097/00007691-199007000-00020. View

Wang P, Beaune P, Kaminsky L, Dannan G, Kadlubar F, Larrey D . Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry. 1983; 22(23):5375-83. DOI: 10.1021/bi00292a019. View

Kaminsky L . Warfarin as a probe of cytochromes P-450 function. Drug Metab Rev. 1989; 20(2-4):479-87. DOI: 10.3109/03602538909103554. View

Sutfin T, Balmer K, BOSTROM H, Eriksson S, Hoglund P, Paulsen O . Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989; 11(2):176-84. DOI: 10.1097/00007691-198903000-00010. View

Wallmark B, Brandstrom A, Larsson H . Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell. Biochim Biophys Acta. 1984; 778(3):549-58. DOI: 10.1016/0005-2736(84)90406-1. View

10.

Fellenius E, Berglindh T, Sachs G, OLBE L, Elander B, Sjostrand S . Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. 1981; 290(5802):159-61. DOI: 10.1038/290159a0. View

11.

Bertilsson L, Henthorn T, Sanz E, Tybring G, Sawe J, Villen T . Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989; 45(4):348-55. DOI: 10.1038/clpt.1989.40. View